11/12/2025 23:00
Xenetic Biosciences, Inc. : Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting
pistrongAdjourns 2025 Annual Meeting of Stockholders/strong/i/ppistrongUrges Stockholders Who Have Not Voted To Get Votes In/strong/i/p pstrong id=datelineFRAMINGHAM, MA / a href=https://www.accessnewswire.com/ACCESS Newswire/a / December 11, 2025 / /stronga rel=nofollow...
19/11/2025 14:45
Xenetic Biosciences, Inc. : Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform
pstrong id=datelineFRAMINGHAM, MA / a href=https://www.accessnewswire.com/ACCESS Newswire/a / November 19, 2025 / /stronga rel=nofollow href=https://pr.report/gb6vXenetic Biosciences, Inc./a NASDAQ:XBIO "Xenetic" or the "Company", a biopharmaceutical company focused on advancing...
13/11/2025 14:45
Xenetic Biosciences, Inc. : Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results
pistrongContinued execution on collaborations and exploratory investigatorinitiated studies with institutional partners/strong/i/ppistrongSecured net proceeds of approximately $3.9 million from October 2025 offering/strong/i/p pstrong id=datelineFRAMINGHAM, MA / a...
10/10/2025 15:30
Xenetic Biosciences, Inc. : Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock
pstrong id=datelineFRAMINGHAM, MA / a href=https://www.accessnewswire.com/ACCESS Newswire/a / October 10, 2025 / /strongXenetic Biosciences, Inc. NASDAQ:XBIO "Xenetic" or the "Company", a biopharmaceutical company focused on advancing innovative immunooncology technologies...
13/08/2025 14:00
Xenetic Biosciences, Inc. : Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results
pistrongExpanded strategic partnership with The Scripps Research Institute to advance proofofconcept studies and further develop its program combining systemic DNase I with CAR Tcell therapies/strong/i/ppistrongEnded the quarter with $4.8 million of cash to fund operations/strong/i/p pstrong...
30/07/2025 15:00
Xenetic Biosciences, Inc. : Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma
pistrongInvestigator initiated study with collaboration partner, PeriNess, to be conducted at the TelAviv Sourasky Medical Center/strong/i/p pstrong id=datelineFRAMINGHAM, MA / a href=https://www.accessnewswire.com/ACCESS Newswire/a / July 30, 2025 / /stronga rel=nofollow...
23/07/2025 14:30
Xenetic Biosciences, Inc. : Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
pistrongResearch and development collaboration program to include additional models of lymphoma and leukemia to further validate DNaseI data demonstrated to date/strong/i/p pstrong id=datelineFRAMINGHAM, MA / a href=https://www.accessnewswire.com/ACCESS Newswire/a / July 23, 2025 / /stronga...
08/07/2025 15:00
Xenetic Biosciences, Inc. : Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic C
pistrongInvestigator initiated exploratory clinical study being conducted in Israel pursuant to agreement with collaboration partner, PeriNess/strong/i/ppistrongCompany evaluating systemic recombinant human DNase I DNase I in combination with chemotherapy and immunotherapy platforms for the...
14/05/2025 14:05
Xenetic Biosciences, Inc. : Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
pistrongStrategic focus on exploratory investigatorinitiated clinical studies with institutional partners/strong/i/ppistrongContinued progress of DNase I development program towards IND and firstinhuman study for treatment of pancreatic carcinoma/strong/i/ppistrongEnded the quarter with $5.2...